Conformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036

Wayne W. Chan(Tufts Medical Center), Scott Wise(Deciphera Pharmaceuticals (United States)), Michael D. Kaufman(Deciphera Pharmaceuticals (United States)), Yu Mi Ahn(Deciphera Pharmaceuticals (United States)), Carol L. Ensinger(Deciphera Pharmaceuticals (United States)), Torsten Haack(Deciphera Pharmaceuticals (United States)), Molly M. Hood(Deciphera Pharmaceuticals (United States)), Jennifer Jones(Deciphera Pharmaceuticals (United States)), John Lord(Deciphera Pharmaceuticals (United States)), Wei Lu(Deciphera Pharmaceuticals (United States)), David F. Miller(Deciphera Pharmaceuticals (United States)), William C. Patt(Deciphera Pharmaceuticals (United States)), Bryan D. Smith(Deciphera Pharmaceuticals (United States)), Peter A. Petillo(Deciphera Pharmaceuticals (United States)), Thomas J. Rutkoski(Deciphera Pharmaceuticals (United States)), Hanumaiah Telikepalli(Deciphera Pharmaceuticals (United States)), Lakshminarayana Vogeti(Deciphera Pharmaceuticals (United States)), Tony Yao(Deciphera Pharmaceuticals (United States)), Lawrence Chun, Robin Clark, Peter Evangelista(Tufts Medical Center), L. Cristina Gavrilescu(Tufts Medical Center), Katherine Lazarides(Tufts Medical Center), Virginia M. Zaleskas(Tufts Medical Center), Lance J. Stewart, Richard A. Van Etten(Tufts Medical Center), Daniel L. Flynn(Deciphera Pharmaceuticals (United States))
Cancer Cell
April 1, 2011
Cited by 205Open Access
Full Text

Abstract


Related Papers

No related papers found

Powered by citation graph analysis